{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020097","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.099208+00:00","generated_at":"2026-06-15T06:36:34.364735+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"PMV Pharma reports Q1 net loss $19.1M; PC14586 trial advances","bullets":["Net loss Q1 2023 $19.1M vs $18.4M Q1 2022; cash & equivalents $229.4M.","R&D expenses $15.1M (up from $11.8M) due to increased clinical costs for PC14586.","Phase 1/2 PYNNACLE study of PC14586 ongoing; next update expected in 2H 2023.","Enrollment commenced in combination arm of PC14586 with KEYTRUDA (pembrolizumab).","Net cash used in operations $15.0M vs $18.0M in prior year period."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020097","json":"https://secwatch.observer/filing/0000950170-23-020097.json","markdown":"https://secwatch.observer/filing/0000950170-23-020097.md","text":"https://secwatch.observer/filing/0000950170-23-020097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000095017023020097/0000950170-23-020097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000095017023020097/pmvp-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:36:34.364735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af952d8e5f9dac4e193b082622ff9b4219f24bc5","claim":"PMV Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss for the quarter ended March 31, 2023, was $19.1 million.","evidence_excerpt":"PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000095017023020097/0000950170-23-020097-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss for the quarter ended March 31, 2023, was $19.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}